Tiziana Life Sciences: against COVID-19 Company
Entity: Tiziana Life Sciences
Category: Vaccine Development
Description: Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).
Project: TZLS-501.
Summary: Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation. When it comes to treating this quick-spreading virus, speed is also vital. The UK biotech Tiziana Life Sciences have accelerated development of their TZLS-501 treatment in the hope that it can help patients suffering from respiratory failure.
“Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.” – Tiziana Life Sciences
Category: Vaccine Development
Description: Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently completing phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy and has filed an IND to enroll patients in an exploratory trial in Hepatic Cellular Carcinoma (HCC).
Project: TZLS-501.
Summary: Tiziana Life Sciences is developing its monoclonal antibody named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human anti-interleukin-6 receptor (IL-6R), which helps in preventing lung damage and elevated levels of IL-6. The drug works by binding to IL-6R and depleting the amount of IL-6 circulating in the body thereby reducing chronic lung inflammation. When it comes to treating this quick-spreading virus, speed is also vital. The UK biotech Tiziana Life Sciences have accelerated development of their TZLS-501 treatment in the hope that it can help patients suffering from respiratory failure.
“Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.” – Tiziana Life Sciences
Technology:
Vaccine Development
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership